Table 3.
Multivariable analysis of recurrence-free survival including clinicopathological and molecular features for MMRd, p53abn and NSMP endometrial cancers.
| MMRd EC (n = 206, 58 events) | p53abn EC (n = 164, 85 events) | NSMP EC (n = 202, 60 events) | |||||||
|---|---|---|---|---|---|---|---|---|---|
| HR | 95% CI | p-value | HR | 95% CI | p-value | HR | 95% CI | p-value | |
| Age | |||||||||
| ≤60 years | 1 | NP | NP | ||||||
| >60 years | 1.55 | 0.88–2.74 | 0.13 | ||||||
| Stage | |||||||||
| I–II | 1 | 1 | 1 | ||||||
| III | 2.33 | 1.36–3.98 | 0.002 | 3.66 | 2.34–5.72 | <.001 | 2.18 | 1.27–3.75 | 0.005 |
| Histology and grade | |||||||||
| Endometrioid, low-grade | 1 | ||||||||
| Endometrioid, high-grade | NP | NP | 2.39 | 1.16–4.94 | 0.018 | ||||
| Non-endometrioid | 1.54 | 0.63–3.81 | 0.35 | ||||||
| Treatment received | |||||||||
| RT (VBT or EBRT) | NP | 1 | 1 | ||||||
| RT (VBT or EBRT) + CT | 0.56 | 0.33–0.93 | 0.025 | 0.44 | 0.22–0.88 | 0.020 | |||
| ER IHC | |||||||||
| Negative (<10%) | NP | NP | 1 | ||||||
| Positive (≥10%) | 0.33 | 0.15–0.75 | 0.008 | ||||||
Model fit multivariable models: MMRd (AIC 510.85, C-index 0.63), p53abn (AIC 652.18, C-index 0.67), NSMP (AIC 499.16, C-index 0.70). Bootstrap resampling model validation: MMRd (C-index re-estimation 0.64), p53abn (C-index re-estimation 0.68), NSMP (C-index re-estimation 0.70).
MMRd mismatch repair-deficient, EC endometrial cancer, p53abn p53-abnormal, NSMP no specific molecular profile, HR hazard ratio, CI confidence interval, NP not performed, LVSI lymphovascular space invasion, RT radiotherapy, VBT vaginal brachytherapy, EBRT external beam radiotherapy, CT chemotherapy.